Regorafenib 3 trial stopped after meeting primary endpoint

A Phase 3 trial of the multi-kinase inhibitor, regorafenib, for patients with metastatic colorectal cancer has met its primary endpoint of a statistically significant improvement in overall survival, according to Onyx Pharmaceuticals Inc.